• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Getinge

192.35 SEK

-0.80 %

Less than 1K followers

GETI B

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.80 %
-2.11 %
+6.51 %
-12.09 %
-9.82 %
+5.25 %
+3.97 %
-39.17 %
+2,329.17 %

Getinge is a Swedish global medical technology company specializing in providing equipment and IT systems to the healthcare and life science industries. The company offers solutions for operating rooms, intensive care units, sterilization centers, and drug development, among other things. The company was founded in 1904 and is headquartered in Gothenburg.

Read more
Market cap
52.39B SEK
Turnover
56.75M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17.7.
2026

Interim report Q2'26

20.10.
2026

Interim report Q3'26

26.1.
2027

Annual report '26

Getinge, Audiocast, Q2'26
Webcast7/17/2026, 8:00 AM

Getinge, Audiocast, Q2'26

Getinge
Press release6/2/2026, 1:00 PM

Getinge Launches Vasoview Hemopro 3, Advancing Endoscopic Vessel Harvesting

Getinge
Press release5/28/2026, 4:35 PM

Getinge's subsidiary Maquet Cardiovascular receives adverse jury trial verdict in patent infringement dispute with Abiomed in the U.S.

Getinge

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release4/21/2026, 3:10 PM

Resolutions at Getinge's Annual General Meeting April 21, 2026

Getinge
Getinge, Audiocast, Q1'26
Webcast4/21/2026, 11:00 AM

Getinge, Audiocast, Q1'26

Getinge
Regulatory press release4/21/2026, 10:00 AM

Getinge Interim Report January-March 2026: Organic growth, strong cash flow and regulatory milestone

Getinge
Press release4/16/2026, 12:30 PM

Modular Finance IR Consensus: Getinge – Consensus estimates Q1 2026

Getinge
Press release4/7/2026, 7:00 AM

Getinge invites fund managers, analysts, and media to Q1 Report 2026 conference call

Getinge
Regulatory press release3/26/2026, 9:00 AM

Getinge publishes Annual Report for 2025

Getinge
Regulatory press release3/12/2026, 7:00 AM

Getinge: NOTICE OF ANNUAL GENERAL MEETING IN GETINGE AB (PUBL)

Getinge
Getinge, Audiocast, Q4'25
Webcast1/27/2026, 9:00 AM

Getinge, Audiocast, Q4'25

Getinge
Regulatory press release1/27/2026, 7:00 AM

Getinge Q4 and Full-Year Report 2025: Organic growth and solid cash flow to end the year

Getinge
Press release1/22/2026, 1:30 PM

Modular Finance IR Consensus: Getinge – Consensus estimates Q4 2025

Getinge
Press release1/13/2026, 7:00 AM

Getinge invites fund managers, analysts, and media to Year-End Report 2025 conference call

Getinge
Regulatory press release12/18/2025, 8:00 AM

Camilla Sylvest is proposed for Getinge AB's Board of Directors

Getinge
Getinge, Audiocast, Q3'25
Webcast10/21/2025, 8:00 AM

Getinge, Audiocast, Q3'25

Getinge
Regulatory press release10/21/2025, 6:00 AM

Getinge Interim Report July-September 2025: High organic sales growth and stronger margins despite geopolitical headwinds

Getinge
Press release10/16/2025, 2:00 PM

Modular Finance IR Consensus: Getinge – Consensus estimates Q3 2025

Getinge
Press release10/13/2025, 8:00 AM

Getinge's Advanta V12 receives CE Mark for major bridging indications

Getinge
Press release10/7/2025, 6:00 AM

Getinge invites fund managers, analysts, and media to Q3 Report 2025 conference call

Getinge